Stocks to watch: 5 companies that could be set to rise

Salesforce shares have slipped 12.9% over the past month to $229.79, and sit 13% below their 52-week high. Over the past year the stock is down 3%. When a company's long-term trend is still pointing up, a short pullback like this can give new buyers a better entry price. A dip can also be the start of a longer slide, so the reasons behind it matter.

At about 21.0 times earnings, the stock is priced below its own recent history. Its price-to-earnings ratio was 65.7 in 2024, 53.0 in 2025, 27.0 in 2026, an average of 48.6. A lower multiple than usual can mean the market is underpricing the business, or that investors expect slower growth ahead.

In the quarter ended Jul 31, 2026, earnings per share rose 119% to $4.29 and revenue grew 11% to $11.35B, compared with the same quarter a year earlier.

Over the last 3 fiscal years, revenue has grown at a compound annual rate (CAGR) of 9.8%, while earnings per share at 233.7% a year.

We found little recent news coverage, so sentiment is neutral in our score.

We found no notable government, regulatory or trade-policy headlines for Salesforce in the past month.

Insiders have also been buying: 1 insider purchased $999K of stock on the open market in the past 90 days.

Dexcom shares have slipped 3.1% over the past month to $86.90, and sit 6% below their 52-week high. Over the past year the stock is up 31%. When a company's long-term trend is still pointing up, a short pullback like this can give new buyers a better entry price. A dip can also be the start of a longer slide, so the reasons behind it matter.

At about 38.1 times earnings, the stock is priced below its own recent history. Its price-to-earnings ratio was 95.5 in 2023, 54.8 in 2024, 31.8 in 2025, an average of 60.7. A lower multiple than usual can mean the market is underpricing the business, or that investors expect slower growth ahead.

In the quarter ended Jun 30, 2026, earnings per share rose 42% to $0.64 and revenue grew 13% to $1.31B, compared with the same quarter a year earlier.

Over the last 3 fiscal years, revenue has grown at a compound annual rate (CAGR) of 17.0%, while earnings per share at 36.6% a year.

We found little recent news coverage, so sentiment is neutral in our score.

We found no notable government, regulatory or trade-policy headlines for Dexcom in the past month.

Expedia Group shares have slipped 14.2% over the past month to $260.17, and sit 23% below their 52-week high. Over the past year the stock is up 20%. When a company's long-term trend is still pointing up, a short pullback like this can give new buyers a better entry price. A dip can also be the start of a longer slide, so the reasons behind it matter.

At about 16.3 times earnings, the stock is priced below its own recent history. Its price-to-earnings ratio was 28.2 in 2023, 20.5 in 2024, 28.7 in 2025, an average of 25.8. A lower multiple than usual can mean the market is underpricing the business, or that investors expect slower growth ahead.

In the quarter ended Jun 30, 2026, earnings per share rose 189% to $7.16 and revenue grew 14% to $4.32B, compared with the same quarter a year earlier.

Over the last 3 fiscal years, revenue has grown at a compound annual rate (CAGR) of 8.1%, while earnings per share at 65.3% a year.

We found little recent news coverage, so sentiment is neutral in our score.

We found no notable government, regulatory or trade-policy headlines for Expedia Group in the past month.

Incyte shares have slipped 10.8% over the past month to $114.13, and sit 12% below their 52-week high. Over the past year the stock is up 32%. When a company's long-term trend is still pointing up, a short pullback like this can give new buyers a better entry price. A dip can also be the start of a longer slide, so the reasons behind it matter.

At about 16.1 times earnings, the stock is priced below its own recent history. Its price-to-earnings ratio was 23.7 in 2023, 460.5 in 2024, 15.4 in 2025, an average of 166.5. A lower multiple than usual can mean the market is underpricing the business, or that investors expect slower growth ahead.

In the quarter ended Mar 31, 2026, earnings per share rose 84% to $1.47 and revenue grew 21% to $1.27B, compared with the same quarter a year earlier.

Over the last 3 fiscal years, revenue has grown at a compound annual rate (CAGR) of 14.8%, while earnings per share at 61.6% a year.

We found little recent news coverage, so sentiment is neutral in our score.

We found no notable government, regulatory or trade-policy headlines for Incyte in the past month.

Welltower shares have slipped 7.0% over the past month to $224.16, and sit 11% below their 52-week high. Over the past year the stock is up 30%. When a company's long-term trend is still pointing up, a short pullback like this can give new buyers a better entry price. A dip can also be the start of a longer slide, so the reasons behind it matter.

At about 100.5 times earnings, the stock is priced below its own recent history. Its price-to-earnings ratio was 129.8 in 2023, 78.0 in 2024, 132.1 in 2025, an average of 113.3. A lower multiple than usual can mean the market is underpricing the business, or that investors expect slower growth ahead.

In the quarter ended Mar 31, 2026, earnings per share rose 155% to $1.02 and revenue grew 38% to $3.35B, compared with the same quarter a year earlier.

Over the last 3 fiscal years, revenue has grown at a compound annual rate (CAGR) of 22.7%, while earnings per share at 66.7% a year.

Recent news coverage has been mixed. Among the headlines: “Meet the Vanguard ETF That Increased Its SpaceX Holding by 39 % in 1 Month and Shows No Signs of Slowing Down”.

We found no notable government, regulatory or trade-policy headlines for Welltower in the past month.

Insiders have also been buying: 1 insider purchased $2.4M of stock on the open market in the past 90 days.